Medical/Pharmaceuticals
China Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity
HAIKOU, China, May 14, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that, in view of the unusual market activity in the common stock of China Pharma on May 1...
2026-05-14 20:56
6826
VARON Celebrates Older Americans Month by Supporting Healthy Aging and Independence
NEW YORK, May 14, 2026 /PRNewswire/ -- This May, in honor of Older Americans
Month, VARON
2026-05-14 19:06
3147
So-Young to Report First Quarter 2026 Financial Results on May 22, 2026
BEIJING, May 14, 2026 /PRNewswire/ -- So-Young International Inc. (NASDAQ: SY) ("So-Young" or the "Company"), the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments, today announced that it will report its financial results for the first...
2026-05-14 17:00
4062
EBT Medical and NinaMED Announce US$13.75M Financing to Advance Licensed NiNA System® for Overactive Bladder
* US$13.75M financing completed to accelerate clinical pathway and global commercialisation * Establishment of NinaMED Pty Ltd, a new Australian medtech company * NinaMED Pty Ltd secures a license from EBT Medical for exclusive global rights to NiNA System®, a non‑invasive, at‑home OAB thera...
2026-05-14 13:03
3535
METiS TechBio, the World's First Publicly Listed AI-Powered Drug Delivery Company, Debuts on the Hong Kong Stock Exchange, "The SpaceX of Pharmaceuticals" Ushers in a New Era of Biopharmaceuticals
HONG KONG, May 13, 2026 /PRNewswire/ -- METiS TechBio (7666.HK), a tech-bio company focused on AI-powered nanodelivery innovation, today successfully listed on the Hong Kong Stock Exchange (HKEX), becoming the world's first publicly listed AI-powered drug delivery company and the first AI-powered...
2026-05-14 10:09
5161
Elabscience® Launches Self-Developed PolyHRP-Streptavidin Conjugate for Low-Abundance Biomarker Detection in ELISA
HOUSTON, May 13, 2026 /PRNewswire/ -- Elabscience® Bionovation Inc. ("Elabscience®" or "the Company") today announced the launch of its self-developed PolyHRP-Streptavidin conjugate, a signal amplification reagent designed to improve enzyme-linked immunosorbent assay (ELISA) sensitivity for low-...
2026-05-14 00:00
3670
Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility
* The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialized solutions for payload-linkers. * This cutting-edge suite will significantly enhance the company's ability to support global payload-linke...
2026-05-13 22:45
3994
High-Trend International Group Announces Pricing of $15 Million Registered Direct Offering with Global Institutional Investors
NEW YORK, May 13, 2026 /PRNewswire/ -- High-Trend International Group (NASDAQ: HTCO) ("HTCO" or the "Company"), a global ocean transportation company, today announced that it has entered into securities purchase agreements with global institutional investors for the purchase and sale of 2,307,700...
2026-05-13 20:00
5367
New Nature Communications Publication Highlights Efsubaglutide Alfa's Effects on Glycaemia and β-Cell Function
HONG KONG, May 12, 2026 /PRNewswire/ -- A major new clinical study, SUPER 2, has been published in Nature Communications, reporting that Efsubaglutide Alfa, a long-actingGLP-1 receptor agonist, significantly improved glycaemic control in adults with type 2 diabetes inadequately controlled on metf...
2026-05-13 11:47
4132
WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index
SHANGHAI, May 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that, in recognition of its continued efforts and exceptional performance in advancing sustainability, the Company has been included i...
2026-05-13 11:33
4752
Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions
SAN FRANCISCO and SUZHOU, China, May 12, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2026-05-13 08:00
5445
Porton Advanced and Dark Horse Consulting Group Announce Memorandum of Understanding Providing A Streamlined Path to Conducting IITs in China
CRANBURY, N.J. and SUZHOU, China, May 12, 2026 /PRNewswire/ -- Porton Advanced, a premier contract development and manufacturing organization (CDMO) specializing in Advanced Therapy Medicinal Products (ATMPs), and Dark Horse Consulting Group ("DHCG" or "the Group"), a leader in strategic and oper...
2026-05-12 23:00
5993
Insilico Medicine and Ribo Enter Strategic Collaboration Agreement: Leveraging AI Platform and Automated Lab for End-to-End Empowerment of RNA Interference and Oligonucleotide Therapeutics Development
SHANGHAI, May 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a biotechnology company powered by generative artificial intelligence , today announced that the company has entered a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd. ("Ribo", 06938.HK), a ...
2026-05-12 20:30
4853
DNA 'barcodes' help NUS researchers pinpoint gold nanoparticles that can strike cancer at its power source
A new high-throughput platform screens dozens of nanoparticle designs in living systems to identify those that reach tumour mitochondria, enabling more precise and effective cancer therapies SINGAPORE, May 12, 2026 /PRNewswire/ -- Researchers at the National University of Singapore (NUS) have de...
2026-05-12 14:59
6723
GIP Moves from Supporting Role to Key Variable: BrightGene Bio-Medical's Phase III Results Signal Differentiation in Weight Loss Arena
SUZHOU, China, May 12, 2026 /PRNewswire/ -- As competition in the weight loss drug market progressively intensifies, the latest Phase III clinical data disclosed by BrightGene Bio-Medical (688166.SH) for BGM0504 has reignited market attention. Mean weight reduction of 19.3%, waist circumference ...
2026-05-12 14:08
3100
Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology
Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help advance medicines for patients worldwide Agreements include 13 programs with the potential to address significant unmet patient needs and support long‑term growth SHANGHAI and PRINCETON, N.J.,...
2026-05-12 12:27
3922
Ranok Therapeutics Announces the Publication of Positive Phase 1a Clinical Results for KRAS G12D Inhibitor RNK08954 in Cancer Discovery
BOSTON and HANGZHOU, China, May 11, 2026 /PRNewswire/ -- Ranok Therapeutics, a clinical-stage biotechnology company developing innovative therapies, today announced the publication of preliminary clinical results from its Phase 1a study of RNK08954 in the peer-reviewed journal Cancer Discovery. R...
2026-05-11 21:00
5520
Leads Biolabs R&D Symposium: Platform Synergy and Multi-Mechanism Integration Reshape the Immuno-Oncology Landscape
NANJING, China, May 11, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) successfully held its R&D Symposium in Shanghai. Under the theme "Leads Innovation, Future Forward", the event comprehensively presented the Company's strategic elevation from "mul...
2026-05-11 19:00
5680
ACROBiosystems Launches Global License Solution Upgrade for HEK293 Functional Cell Lines, Streamlining Compliance to Accelerate Biopharmaceutical R&D
NEWARK, Del., May 9, 2026 /PRNewswire/ -- ACROBiosystems has implemented a major upgrade to its global licensing framework for HEK293 functional cell lines, transitioning from a complex administrative process to a streamlined, purchase-based authorization model. This policy shift addresses the i...
2026-05-10 01:30
7082
World's First | Mabwell's 9MW5211 Receives FDA Clearance for Clinical Trial Application
SHANGHAI, May 8, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Investigational New Drug (IND) application for 9MW5211, its independently developed novel antibody, has received clearance...
2026-05-09 08:00
7090
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 279 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
Vestas Powers Up Vietnam's Clean Energy Ambitions with Two New Projects Under PDP8 Totaling 16 Wind Turbines
[Picked up by 263 media titles]
2026-10-02 16:27
Southeast Asia's China travel map is widening, Traveloka platform data shows
[Picked up by 262 media titles]
2026-10-05 11:51Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
24261